Reducing UV Exposure to Prevent Skin Cancer: Message Development & Testing
Phase 3b of the research will be a laboratory experiment that uses an experimental and analytic design that is parallel to that used in Phase 3a, the online experiment. The primary objective of Phase 3b is to assess physiological response (i.e., eye tracking) to different message appeals of the audio-visual messages used in Phase 3a on respondents' behavioral intentions and UV-related behavioral choices post-exposure. Including time for preparation, viewing, and removal of the monitoring equipment, the message viewing session will take about 45 minutes per session.
NCT03201120 — Behavior, Health
Status: Completed
http://inclinicaltrials.com/behavior-health/NCT03201120/
Self-Monitoring and Readiness Texting Project (SMART)
This pilot clinical trial studies how well Self Monitoring And Readiness Texting (SMART) project works in sun exposure and protection behaviors. Measuring how behavior tracking and individually tailored messages affect risk behaviors in patients with skin cancer may help doctors plan the best prevention plan and decrease national melanoma incidence and mortality.
NCT03177057 — Skin Carcinoma
Status: Completed
http://inclinicaltrials.com/skin-carcinoma/NCT03177057/
Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach
This study will have two phases, with an added usability test after Phase I and before Phase 2. Phase 1: Cognitive Interviews of materials in Spanish. Phase 2: Personalized Genomic Testing for Skin Cancer (PGT-SC). The overarching goal of this study is to learn more about how to maximize the availability, comprehension and appropriate uptake of personalized genomics among different populations in New Mexico. Primary Care patients will be recruited in their primary health clinic to complete surveys about their understanding and beliefs of skin cancer and behaviors that might help prevent skin cancer. 6 out of every 7 patients will then be asked to go to a website to learn more about skin cancer risk. Once participants have completed the education modules on this site, participants will be given the option to request and complete a skin cancer genetic testing kit. All participants will be contacted again after three months to complete a follow-up set of surveys about skin cancer.
NCT03130569 — Melanoma (Skin)
Status: Completed
http://inclinicaltrials.com/melanoma-skin/NCT03130569/
TLR4 Polymorphisms and Predisposition for Skin Cancer Development
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.
NCT03122366 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT03122366/
Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risks in Alabama Population
The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics.
NCT03040492 — Skin Cancer, Non-Melanoma
Status: Active, not recruiting
http://inclinicaltrials.com/skin-cancer-non-melanoma/NCT03040492/
Pretreatment With Ablative Fractional Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin
Comparison of treatment efficacy and safety of pretreatment with ablative fractional laser versus microdermabrasion combined with large-area photodynamic therapy with methyl aminolevulinate for actinic keratoses
NCT03006185 — Actinic Keratosis
Status: Completed
http://inclinicaltrials.com/actinic-keratosis/NCT03006185/
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
NCT02964559 — Skin Squamous Cell Carcinoma
Status: Active, not recruiting
http://inclinicaltrials.com/skin-squamous-cell-carcinoma/NCT02964559/
PERSONALIZED GENOMIC TESTING FOR MELANOMA: MAXIMIZING COMPREHENSION AND HEALTH OUTCOMES IN SKIN CANCER PATIENTS
The purpose of this study is to learn whether the patient might be interested in skin cancer genetic testing, and if so, what kinds of thoughts, feelings, and behaviors might result from this testing. Testing for skin cancer risk based on the MC1R gene is not currently used in clinical practice; it will be offered in this study for research purposes only.
NCT02941900 — Non-melanoma Skin Cancer (NMSC)
Status: Completed
http://inclinicaltrials.com/non-melanoma-skin-cancer-nmsc/NCT02941900/
A Randomized Assessor-blinded Comparison of Low Irradiance and Conventional Irradiance Photodynamic Therapy (PDT) for Superficial Non-melanoma Skin Cancer
This study aims to examine whether the pain of topical photodynamic therapy (PDT) is significantly different when using low irradiance ambulatory light emitting diode (LED) devices compared with conventional higher irradiance hospital based LED light sources when used for superficial non-melanoma skin cancer. The investigators are also investigating the phototoxicity and efficacy of each regime in this randomized assessor-blinded clinical trial.
NCT02872909 — Non-melanoma Skin Cancer
Status: Completed
http://inclinicaltrials.com/non-melanoma-skin-cancer/NCT02872909/
A Pilot Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
This proposal describes a pilot study to gather preliminary evidence of efficacy, tolerability and toxicity of oral PLE among a high-risk skin cancer population for the prevention of Actinic keratosis (AKs) and keratinocytes (KCs) to gain insight into optimal methods for recruitment, intervention development, data collection, and promoting protocol adherence prior to conducting a fully powered trial. The primary clinical outcome is AKs as measured by a clinical dermatologist, with skin cancer as a secondary clinical outcome. The investigators will also assess histologic markers of Ultra Violet (UV) damage, which have previously been shown to be reduced with oral PLE use in human studies, namely formation of UV-induced cyclo pyrimidine dimer positive cells and number of sunburn cells among epidermal keratinocytes. Results generated from this proposal will form the foundation of a fully powered clinical trial of the effect of PLE on the risk of AKs and KCs. The results may also provide information about this promising dietary supplement which may provide extra protection for a high-risk skin cancer population.
NCT02813902 — Skin Neoplasms
Status: Withdrawn
http://inclinicaltrials.com/skin-neoplasms/NCT02813902/